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ABSTRACT
Objective: To develop a model to predict stroke-free survival
and mortality over a multiyear time frame for a trial-
excluded population of medically managed asymptomatic
patients with signiﬁcant carotid artery stenosis.
Methods: We calibrated, validated, and applied a Monte
Carlo microsimulation model. For calibration we adjusted
general-population mortality and stroke risks to capture
these risks speciﬁc to asymptomatic carotid stenosis patients.
For validation, we compared model-predicted and actual
stroke-free survival curves and stroke counts from a popula-
tion of comparable patients. For application, the validated
model predicted stroke-free survival for a hypothetical medi-
cally managed arm of a recent single-arm carotid revascular-
ization trial.
Results: For each month in the 60-month time frame, the
model-predicted and actual calibration trial stroke-free sur-
vival curves were not statistically different (P > 0.62). In vali-
dation, the calibrated model’s stroke-free survival curve
matched the actual curve from an independent population;
beyond 24 months, the model-predicted and actual curves
were not statistically different (P > 0.32). We also compared
model-predicted and actual number of strokes from the inde-
pendent trial. The model predicted 187.25 strokes (95%
conﬁdence interval 161.49–213.01), while the actual number
was 171.6, within 1.22 standard deviations of the simulated
mean.
Conclusions: Given the absence of medically managed popu-
lations in recent carotid stenosis trials, our model can
estimate stroke-free survival and mortality data for these
patients. The model may also estimate the effectiveness of
novel medical and procedural therapies for stroke preven-
tion. These effectiveness estimates can inform the develop-
ment of policies, guidelines, or cost-effectiveness analyses
when only single-arm trial data exist.
Keywords: asymptomatic carotid artery stenosis, medical
therapy, microsimulation, model, stroke.
Introduction
Randomized controlled clinical trials [1–3] have
shown that carotid endarterectomy is superior to
medical treatment for reducing the risk of stroke in
patients with asymptomatic carotid stenosis [4].
Therefore, the designers of later trials [5–8] evaluating
more current carotid revascularization interventions
for such patients considered it unethical to compare
the interventions to medical treatment. Additionally,
because contemporary medical treatment had not fun-
damentally advanced since the prior carotid endarter-
ectomy trials, a medical therapy arm was not in-
cluded in these more current revascularization trials.
Nevertheless, a high level of interest remains as to how
medically managed patients would fare against the
intervention groups in these revascularization trials,
especially among clinicians, patients, or policymakers.
Typically, these groups must observe a signiﬁcant rela-
tive risk reduction of adverse outcomes before recom-
mending or accepting an intervention with attendant
short-term risks. Interest from these groups provides
the motivation to create a model to simulate these
trial-excluded medically managed patients.
The model outputs can serve as a surrogate for trial
results from medically managed patients not included
in recent trials, and thereby aid in the evaluation of
advances in revascularization and medical therapies.
Furthermore, because clinical trials are rarely repeated,
simulation models may serve a role to update previous
trials and to extrapolate previous results to other
patient populations.
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The primary study objective was to develop a model
to predict stroke and mortality over a multiyear time
frame for a population of medically managed patients
with substantial (>60%) asymptomatic carotid artery
stenosis. This objective included validation of themodel
with independent clinical trial data. A secondary objec-
tivewas to use themodel to predict stroke andmortality
for comparable patients who are at considerably higher
risk for complications from surgical revascularization
than patients against which the model was validated.
Methods
Model Overview
We developed a microsimulation model with discrete-
event features to estimate stroke-free survival and
mortality for a population of asymptomatic patients
with substantial carotid artery stenosis receiving con-
temporary medical therapy. Model development con-
sisted of three major processes: model calibration,
validation, and application (see Fig. 1).
The calibration process began with standard
methods for determining general-population mortality
and stroke risks. These standard methods were
adjusted to capture the stroke and mortality risks par-
ticular to a clinical trial population of asymptomatic
patients with substantial carotid artery stenosis. In the
validation process, model-predicted stroke and mortal-
ity outcomes were statistically compared with actual
outcomes from an independent clinical trial popula-
tion of comparable patients. In the model application
process, the validated model was used to predict stroke
and mortality for a hypothetical medically managed
arm of a recent single-arm carotid revascularization
trial that did not include a contemporary medically
managed group.
For model calibration, we used data from the
Asymptomatic Carotid Atherosclerosis Study (ACAS)
[1], for validation we used the Asymptomatic Carotid
Surgery Trial (ACST) [2], and for application we used
the ACCULINK™ for Revascularization of Carotids
in High Risk Patients (ARCHeR) Trial [5].
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Figure 1 Overview of processes for model calibration, validation, and application. ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymp-
tomatic Carotid Surgery Trial;ARCHeR,ACCULINK™ for Revascularization of Carotids in High Risk Patients; CHD, coronary heart disease.
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Model Structure
Figure 2 depicts the model execution process. Each run
of the model simulates one population (a population
loop), which consists of a number of individual
patients (a patient loop). A complete simulation con-
sists of multiple runs, i.e., simulated populations. A
patient loop begins with the creation of an individual
patient. Each patient is uniquely assigned a value for
each of the following 11 characteristics: age, sex,
systolic blood pressure, smoker/nonsmoker, lipid
ratio (total cholesterol/high-density lipoprotein),
electrocardiogram-detected left ventricular hypertro-
phy, diabetes, atrial ﬁbrillation, previous myocardial
infarction, hemoglobin A1c, and years diagnosed dia-
betic (see Supplementary Material—tables A and B).
The model then calculates the patient’s stroke and
death risks, and determines if the patient experiences a
stroke or dies within the model time frame. For each
simulated patient, statistics are collected at the time of
a stroke or death event, or at the end of the 5-year
model time frame. The 5-year time frame corresponds
to the planned follow-up period of the trials upon
which the model was calibrated and validated.
Model Calibration––Mortality and
Stroke-Risk Calculation
The occurrence of nonstroke death was incorporated
into the model because of the advanced age of the
simulated populations and the model’s multiyear time
frame. To capture the effect that clinical trial inclusion/
exclusion criteria have on study subjects’ intermediate-
term (i.e., 1- to 5-year) death probabilities, we
“phased-in” death probabilities from heart disease,
malignant neoplasms (i.e., cancer), chronic lower res-
piratory disease, and liver disease.
To determine patient-speciﬁc stroke risks for the
carotid stenosis population, baseline stroke risks were
ﬁrst calculated using general-population equations
(Framingham [9] for nondiabetics and the United
Kingdom Prospective Diabetes Study [UKPDS] [10] for
diabetic patients). A multiplicative stroke-risk calibra-
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Figure 2 Graphical representation of the model execution process.
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tion factor was then computed to adjust the predicted
stroke occurrence from general-population equations
to the actual stroke occurrence observed from a trial
of medically managed asymptomatic carotid stenosis
patients.
Pharmacologic medical therapy (e.g., statins,
thienopyridines, and aspirin) have been proven to
reduce the incidence of stroke in patients at high risk of
vascular disease [11,12]. Thus, the capability to incor-
porate the stroke-reducing effects of existing and
future medical therapies was incorporated into the
model.
The Supplementary Material contains extensive
detail on the methodology used to implement patient-
speciﬁc mortality and stroke risks into the model.
The model is primarily a Monte Carlo microsimu-
lation model, but takes advantage of a discrete-event
simulation technique to model if and when a speciﬁc
patient dies or has a stroke. First, the model gener-
ates a single (0–1) random number. Second, this
random number is compared with the 60-month
cumulative mortality probability. (The last row of
Appendix––table C displays monthly cumulative mor-
tality probabilities for an example patient.) If the
random number is greater than the 60-month cumu-
lative mortality probability, the model then deter-
mines that the patient does not die in the model time
frame. If the random number is less, successive com-
parisons are made to monthly cumulative mortality
probabilities to assign a month of death. The same
methodology is used to determine if and when a
patient experiences a stroke during the simulation
time frame. The model is described as discrete-event
because for each patient one random number is gen-
erated to predetermine the time of each of their
events (stroke or death, though neither may occur in
the model time frame and stroke events after death
do not actually occur).
This discrete-event methodology requires the model
to generate only one random number per patient per
type of event (i.e., mortality or stroke) to determine if
that event occurs for a particular patient. In ﬁxed-time
advance simulations, a model generates a random
number per model time period (in our case 60 months)
to determine if an event occurred, making the discrete-
event simulation methodology more computationally
efﬁcient. Also, reducing by a factor of 60 (the number
of model time periods), the number of random
numbers generated to determine if an event occurs
greatly simpliﬁes the organization of synchronized
random number streams––a process essential to valid
comparisons between input scenarios and to verifying
the software-based model. As patients do not interact
with each other, discrete-event features such as
queuing and resource constraints that are essential for
infectious disease or facility planning models are not
needed in our model.
Results
Model Calibration––Mortality Risk
We graphically and statistically compared the medi-
cally managed population’s mortality survival curves
from the actual ACAS trial with the simulated ACAS
population, both with and without mortality phase-in.
The simulated ACAS mortality survival curve with
mortality phase-in was a close ﬁt to the actual ACAS
curve and, as expected, markedly higher, i.e., less mor-
tality, than the simulated ACAS curve without mortal-
ity phase-in (see Supplementary Material—ﬁgure A).
All survival curves presented in this manuscript and
Appendix were constructed using the Kaplan–Meier
method.
For statistical comparisons we performed a stan-
dard equality of probabilities test on the simulated and
actual curves at t = 12, 24, 36, 48, and 60 months (see
Supplementary Material––table D). With mortality
phase-in, there was no evidence that the ACAS simu-
lated and actual mortality survival curves had a statis-
tically signiﬁcant difference (0.26 < P < 0.93). Without
mortality phase-in, the ACAS simulated and actual
curves had a statistically signiﬁcant difference
(0 < P < 0.04) at times t  48 months.
Model Calibration––Stroke Risk
Figure 3a displays the effect of incorporating a calibra-
tion stroke-risk factor for carotid stenosis patients
on “Freedom from Stroke” survival curves. (In our
“Freedom from Stroke” survival curves, patients were
censored at their time of nonstroke death.) This ﬁgure
also shows the effect of mortality phase-in on stroke
survival curves and is discussed in the Model Valida-
tion section below.
Model Validation
As a check on our calibration methodology, we ran the
model with ACAS population distributions as inputs
and compared the model outputs to actual ACAS trial
results. These comparisons are displayed in Figure 3a
which shows the simulated and actual results for the
proportion of the ACAS population stroke-free over a
5-year time period.
Figure 3a shows three simulated curves represent-
ing three progressive adjustments to our model cali-
bration methodology. These adjustments addressed
mortality phase-in and stroke-risk modiﬁcations for
substantial carotid stenosis. The top simulated curve
(Series B) is the model output when mortality prob-
abilities from heart disease, cancer, chronic lower res-
piratory disease, and liver disease are not phased in,
and the stroke probabilities are not increased to reﬂect
the patients’ substantial carotid stenosis. The second
highest curve (Series C) incorporates mortality
phase-in for the four diseases, but does not integrate
the effects of substantial carotid stenosis. The third
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simulated curve (Series D) incorporates both mortality
phase-in and increased stroke risk due to substantial
carotid stenosis. Applying the standard equality of
probabilities test to compare the third simulated curve
(Series D) with the actual ACAS trial results (Series A)
yields all P-values > 0.61 (see Table 1), meaning that
there is insufﬁcient evidence to suggest that these two
curves have a statistically signiﬁcant difference.
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Figure 3 (a) Simulated and actual Asymptomatic Carotid Atherosclerosis Study (ACAS) trial “Freedom from Stroke” medically managed survival curves,
patients censored at their time of nonstroke death. Series A: actual ACAS trial data; Series B: simulated ACAS without mortality phase-in, without
stroke-risk calibration; Series C: simulatedACAS with mortality phase-in,without stroke-risk calibration; Series D: simulatedACAS with mortality phase-in,
with stroke-risk calibration. (b) Simulated and actual Asymptomatic Carotid Surgery Trial (ACST) “Freedom from Stroke” medically managed survival
curves, patients censored at their time of nonstroke death. Series A: actual ACST trial data, solid line is linear trend between actual data points (); Series
B: simulated ACST. (c) Simulated and actual ACCULINK™ for Revascularization of Carotids in High Risk Patients (ARCHeR) trial “Freedom from Stroke”
survival curves, patients censored at their time of nonstroke death.X-axis only extends to 24 months becauseARCHeR is an ongoing trial. Series A: actual
ARCHeR intervention trial data, asymptomatic patients only; Series B: simulated medically managed ARCHeR without increased stroke risk for ARCHeR
comorbidities; Series C: simulated ARCHeR medically managed with increased stroke risk for ARCHeR comorbidities.
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After calibration with ACAS data, the model was
validated against the stroke survival data of the ACST
medically managed population. The simulated and
actual results showing the proportion of the ACST
population stroke-free over time are displayed in
Figure 3b. Table 1 presents the absolute differences
between the curves and the P-values from the standard
equality of probabilities tests. The absolute differences
between the curves were low (range 0.9–1.4%), and
beyond 24 months, the curves did not have a statisti-
cally signiﬁcant difference (0.26 < P < 0.42).
For further validation, in the ACST medically
managed population we compared the model-
predicted number of strokes versus the number of
strokes calculated from the actual trial’s 5-year risk of
stroke (11.0%). ACST’s 5-year stroke risk in 1560
medically managed patients yields a mean of 171.60
strokes with a standard deviation of 12.36. The model
predicted a mean of 187.25 strokes with a standard
deviation of 12.89. The actual trial’s mean was 1.22
standard deviations lower than the model-predicted
mean, which is well within the model-predicted mean’s
95% conﬁdence interval.
Model Application
To demonstrate an application of the validated model,
we used the model to estimate the occurrence of stroke
and death for a hypothetical medically managed
ARCHeR population. (The ARCHeR trial design was
single-armed, intervention only. No medical therapy
arm was included; hence, the hypothetical descriptor.)
The ARCHeR simulated medical and actual interven-
tion arm stroke-free survival curves are displayed in
Figure 3c. Rather than presenting a single simulated
survival curve, Figure 3c displays two simulated
ARCHeR survival curves B and C, both of which are
explained below. It is important to note that curves B
and C are not intended to ﬁt curve A. Curves B and
C are estimations (under different assumptions) of
stroke-free survival for a hypothetical medically
managed population––a population not included in
the ARCHeR trial. Curve A presents actual stroke-free
survival for the ARCHeR intervention population.
Furthermore, ARCHeR is an ongoing trial that contin-
ues to gather patient follow-up data. Thus, Figure 3c
only shows 24 months of actual and simulated data.
The ARCHeR population demographics and clini-
cal characteristics are generally consistent with the
ACAS and ACST populations in that they are asymp-
tomatic patients with substantial carotid stenosis.
Nevertheless, the ARCHeR population has, by trial
inclusion criteria, considerably more cardiovascular
comorbidities. In fact, all ARCHeR patients had at
least one risk factor that made them either ineligible or
a high-risk candidate for carotid endarterectomy [13].
Indeed, all ARCHeR patients would have been ineli-
gible to enter the ACAS and ACST trials. Thus, the
ARCHeR patients are similar (in terms of asymptom-
atic carotid stenosis), yet signiﬁcantly different (in
terms of cardiovascular comorbidities) and more
prone to stroke than the ACAS and ACST populations
(see calculations in Supplementary Material—Model
Applications—Simulated ARCHeR Best Estimate Sur-
vival Curve).
Simulated ARCHeR Survival Curve without Adjustment
The “without adjustment” survival curve (Fig. 3c,
Series B) is the simulated result when the ARCHeR
population data are input to the ACAS-calibrated and
ACST-validated model without a stroke-risk adjust-
ment to reﬂect the increased comorbidities of the
ARCHeR population. In other words, the “without
adjustment” curve assumes that the increased stroke
risk of the ARCHeR population is fully captured by
the ARCHeR population inputs to the stroke-risk
equations (see Supplementary Material—table A). The
“without adjustment” scenario assumes that no
stroke-risk adjustment is necessary to reﬂect the
ARCHeR comorbidities that differentiate it from the
ACAS and ACST populations.
Simulated ARCHeR Best Estimate Survival Curve
The “best estimate” survival curve (Fig. 3c, Series C) is
the simulated result when the model’s stroke-risk
equations are multiplied by an adjustment factor to
reﬂect the estimated increased stroke risk of the
ARCHeR population (see Supplementary Material for
calculation details).
Discussion
The purpose of developing such a model is to provide
an analytical framework that allows for the evaluation
of stroke and mortality outcomes in medically
managed populations not included in carotid revascu-
larization clinical trials. Examples include such trials
Table 1 Statistical comparisons between simulated and actual
trial stroke survival curves
Months
12 24 36 48 60
ACAS simulated vs. actual
Stroke survival curves
Absolute difference between
curves (%)
0.2 0.4 0.1 0.5 2.3
P-values, standard equality of
probabilities test
0.82 0.71 0.95 0.82 0.61
ACST simulated vs. actual
Stroke survival curves
Absolute difference between
curves (%)
1.1 1.4 0.9 1.2 1.0
P-values, standard equality of
probabilities test
<0.01 0.03 0.29 0.26 0.42
ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid
Surgery Trial.
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as ARCHeR [5], CREST [6], ACT I [7], and CaRESS
[8]. Furthermore, the model can be used to compare
hypothetical medically managed patient cohorts
against actual patient cohorts in registries such as the
American College of Cardiology’s Carotid Stent Reg-
istry™ [14]. Additionally, the model can be used to
estimate the effectiveness of novel medical and proce-
dural therapies for stroke prevention in asymptomatic
carotid stenosis patients. These effectiveness estimates
can inform the development of policies, guidelines,
and/or cost-effectiveness analyses.
In order for the development of a carotid stenosis
medical therapy model to be feasible and relevant,
a number of issues and factors have to exist. First,
data on stroke and mortality outcomes for medically
managed carotid stenosis patients must be available to
calibrate and validate the model. With our model, data
from the published ACAS and ACST trials satisﬁed
this requirement, though data from additional relevant
studies could serve to enhance the validation of the
model. Second, published and validated stroke, mor-
bidity, and mortality risk equations or data sources
must be available to populate the model. In our model,
the Framingham and UKPDS stroke and coronary
heart disease/myocardial infarction mortality risk
equations, general-population mortality data, and
other published data sources ﬁt this need. Third,
advances in medical therapy for carotid stenosis
patients must be evolutionary (from the time they were
included in carotid endarterectomy trials), rather than
revolutionary. Since this is the case, the evolutionary or
incremental medical therapy advances can be incorpo-
rated into the model. An example is the inclusion of
the higher percentage of carotid stenosis patients
taking statins and the subsequent reduction of stroke
risk for these patients.
Relevant Published Stroke Models
The medical literature includes several studies that use
models to address the occurrence of stroke in medi-
cally managed, asymptomatic persons with substantial
carotid stenosis. The focus of these published models is
either to evaluate screening strategies to reduce stroke
in asymptomatic carotid stenosis patients [15–19] or
to assess carotid endarterectomy versus medical man-
agement in these patients [20–22]. Our model repre-
sents a considerable advancement from these models,
in part because our model incorporates more sophisti-
cated stroke-risk determinations at a patient- and time-
speciﬁc level.
In each of these published models, medically
managed persons with asymptomatic carotid stenosis
were assigned annual stroke risks based solely on their
level of stenosis. In several of the models, all asymp-
tomatic medically managed persons above a given
stenosis level (>60% [16–19,21] and >75% [22]) were
assigned the same annual stroke risk (though the
assigned risk varied between studies). In the other
models, there were more reﬁned strata, e.g., 1% to
29%, 30% to 59%, 60% to 99%, and occlusion [20],
and each person within a stratum received the same
annual stroke risk. Furthermore, for all of the above-
mentioned published studies, the annual stroke risk
did not vary over time, a notable example being the
model [19] that held the medically managed annual
stroke rate constant for 20 years.
In our model, stroke probabilities are calculated
using 11 patient-speciﬁc variables as inputs to vali-
dated and published risk equations (see Supplementary
Material—table A). The implementation of these
established risk equations allows the assigned prob-
abilities to vary as patients age. At present, the model
only varies the age input over time. Nevertheless, the
model is structured to incorporate time-dependent
variations in the other equation inputs. Further studies
will investigate the availability of quality data demon-
strating the time-variation of these inputs and the
effect these time-varying inputs will have on the model
outputs. Also, by creating populations and assigning
characteristics on a patient-by-patient basis, our model
can create and estimate outcomes for patient cohorts
with different mixes of comorbid conditions (as com-
pared with original clinical trials).
Methodological Considerations
Our stroke model was developed, calibrated, vali-
dated, and applied following a multistep iterative
method. First, patient-speciﬁc mortality was predicted
using standard mortality risk tables and excess mortal-
ity risk equations. Then, techniques were developed to
phase-in mortality in the simulated populations to
correct for decreased mortality rates in clinical trials
because of speciﬁc inclusion/exclusion criteria.
General-population stroke-risk equations (Framing-
ham [9] and UKPDS [10]) were calibrated to incorpo-
rate the excess stroke risk due to substantial carotid
stenosis. Subsequently, the model was calibrated
against the stroke-free survival curve constructed from
actual data from the ACAS trial. The calibration
process also involved the inclusion of model features to
simulate the stroke-reducing effects of newer medical
therapy.
Second, the model was validated against a data set
from the ACST trial which was independent of the
ACAS data used for calibration. The validation was
performed by statistical comparison of the ACST
model-predicted and the ACST actual stroke-free sur-
vival curves. Finally, an application of the validated
model was demonstrated by simulating a hypothetical
medical therapy arm of the ARCHeR trial, a popula-
tion with underlying risk factor distributions different
from ACAS and ACST.
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It was during the calibration process that the neces-
sity of mortality phase-in became apparent. As can be
seen in Supplementary Material—ﬁgure A, without
mortality phase-in, the model-predicted mortality rates
for the simulated trial population greatly exceed the
actual trial population’s mortality rates. The patients
at high risk of dying from cardiovascular causes (e.g.,
smokers with diabetes and high systolic blood pres-
sure) are also at high risk of experiencing a stroke.
Therefore, not phasing in cardiovascular mortality
increases early death of patients at high risk for stroke.
This prematurely decreases the pool of high-risk stroke
patients and thereby reduces the occurrence of stroke
in the simulated population.
We learned that in trials such as ACAS and ACST,
the patients, even though they had more than 60%
carotid artery stenosis, had mortality rates markedly
lower than age- and sex-matched general-population
mortality rates. This is most likely from trial inclusion/
exclusion criteria which result in populations with
fewer chronic, life-threatening medical conditions.
Even the ARCHeR trial, whose inclusion criteria
required patients to have advanced heart disease, had
mortality rates slightly below general-population mor-
tality rates.
The calculation of the ARCHeR to ACAS “strokes
per year of postprocedure follow-up” ratio (see
Supplementary Material––Model Application––
Simulated ARCHeR Best Estimate Survival Curve)
assumes that carotid endarterectomy and carotid
stenting are equally effective in preventing stroke
over an approximate 33-month period (median
follow-up was 2.7 years for ACAS and 1.3 years of
follow-up data for the ongoing ARCHeR trial were
available). Two references are presented to support
this assumption. Coward et al. [23] conducted a sys-
tematic review of ﬁve randomized studies that com-
pared the efﬁcacy of endovascular treatment with
surgery for carotid stenosis. (The more general term
“endovascular treatment” was used, as opposed to
stenting, for some patients in one of the ﬁve trials
underwent percutaneous transluminal angioplasty
without stent.) Coward et al. found that at one year
after randomization, there was no signiﬁcant differ-
ence between the two treatments in the rate of any
stroke or death (odds ratio 1.01; conﬁdence interval
0.71–1.44). Yadav et al. [24] conducted a random-
ized trial comparing carotid artery stenting with the
use of an emboli-protection device to endarterectomy
in patients with coexisting conditions. The study’s
primary end point was a composite of death, stroke,
or myocardial infarction within 30 days after the
intervention or death, or ipsilateral stroke between
31 days and one year. The authors concluded that
stenting with protection was not inferior to endarter-
ectomy (P = 0.004) and stenting-approached superi-
ority (P = 0.053).
Limitations
To adjust the general-population stroke-risk equations
to include the excess risk from substantial carotid
stenosis, a two-term calibration factor was calculated
in the form of a + bt, where a and b are constants and
t is the trial follow-up time. A possible limitation of the
model is that this calibration factor only varies with t,
and does not vary with patients’ underlying character-
istics, e.g., their level of stenosis. This may be appro-
priate, though, because data quantifying stroke risk by
stenosis level are inconclusive at best.
Another potential limitation is that when the model,
as currently conﬁgured, creates a simulated patient,
it assigns most patient characteristics independently
from trial population distributions, i.e., the joint dis-
tribution of risk factors assumes conditional indepen-
dence among most of the factors (though the model
does assign sex based on age, and lipid ratio based on
sex). This approach was dictated by the available data.
Nevertheless, our model’s microsimulation structure is
sufﬁciently ﬂexible to accommodate individual patient
data on the joint distribution of risk factors when such
data are available. Additionally, the model outputs
were negligibly different when most characteristics
were independently assigned from distributions versus
assigning characteristics directly from the patient’s
record. This comparison was performed for both the
ACAS and ARCHeR trials.
A further limitation of the model is that the stroke-
risk equations, upon which the model is based, predict
both ischemic and hemorrhagic strokes. At present, the
model does not differentiate between these two types
of stroke, nor does the model differentiate between
ipsilateral and contralateral strokes.
Example Application of Model to a Recent Trial
In the application of our validated model to the
ARCHeR trial population, we devised a novel
approach to quantify the amount by which the model’s
stroke-risk equations underestimate the increased
stroke risk because of the ARCHeR population’s car-
diovascular comorbidities. The results of this approach
produced an ARCHeR stroke-risk correction factor
that was incorporated into the model to more accu-
rately estimate stroke-free survival in a hypothetical
ARCHeR medically managed population.
Conclusion
Given the absence of a medically managed population
in ARCHeR, and a high-level of interest for outcomes
data from such patients, our validated model may be
an informative source of estimated stroke-free survival
data for real-world medical therapy carotid stenosis
patients. As longer-term ARCHeR follow-up data are
collected, we will continue to perform comparisons
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between the ARCHeR actual intervention and the
simulated best-estimate medical therapy stroke-free
survival curves. It is our long-term goal to have the
model act as a tool to provide insight as to whether
carotid stenting in ARCHeR-like populations is asso-
ciated with true reductions in stroke compared with
contemporary medical therapy.
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